Preparation and In Vitro Evaluation of 131I-BmK CT as a Glioma-Targeted Agent

被引:10
|
作者
Zhao, Jinhua [1 ]
Qiao, Wenli [1 ]
Zhang, Yuna [1 ]
Shao, Xiaoxia [2 ]
机构
[1] Shanghai Jiao Tong Univ, Dept Nucl Med, Peoples Hosp 1, Shanghai 200080, Peoples R China
[2] Tongji Univ, Inst Prot Res, Shanghai 200092, Peoples R China
基金
中国国家自然科学基金;
关键词
I-131; glioma; radionuclide therapy; scorpion toxin; targeted therapy; PHASE-I; MALIGNANT GLIOMAS; BRAIN-TUMORS; CHLOROTOXIN; SCORPION; PEPTIDE;
D O I
10.1089/cbr.2009.0704
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Objective: Buthus martensi Karsch (BmK) CT, a kind of scorpion toxin peptide, was found to inhibit glioma cell proliferation in previous researches. I-131-BmK CT may have more inhibition effect and could be used as a glioma cell-targeted therapy and imaging agent. The purpose of this study was to investigate whether I-131-BmK CT could specifically conjugate with C6 glioma cell and induce glioma cell inhibition in vitro. Methods: After cloning, expression, and purification, BmK CT was labeled with I-131 by indirect labeling (Bolton-Hunter method). The cell conjugation experiment was performed to investigate the connection between the reciprocal of cell conjugation rate and the reciprocal of cell count. 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyl-tetrazolium bromide (MTT) method and flow cytometry were used to detect the inhibition effect of BmK CT and I-131-BmK CT on glioma cell proliferation. Results: I-131-BmK CT was successfully prepared with the overall yield of 34.5%. The cell conjugation experiment indicated that I-131-BmK CT could specifically conjugate with C6 cells. MTT tests indicated that both BmK CT and I-131-BmK CT could inhibit C6 growth. The ability of I-131-BmK CT to inhibit cell growth is superior to that of BmK CT. The inhibitory rate (IR) of glioma cells was 60.5% (p < 0.01) at the concentration of 2 mu g/mL with BmK CT. And the IR was 71.2% (p < 0.01) at the radioactivity concentration of 50 mu Ci/mL (concentration was much lower than 2 mu g/mL) with I-131-BmK CT. BmK CT could block the C6 glioma cell cycle in the G0/G1 stage. I-131-BmK CT blocked the cell cycle in the S stage (the proportions of C6 in the S, G0/G1, and G2/M phases were 24.5% +/- 0.4% vs. 44.0% +/- 2.3%, 63.9% +/- 0.6% vs. 51.8% +/- 1.6%, and 11.6% +/- 1.0% vs. 4.3 +/- 0.7% [p < 0.05], respectively, at an initial radioactivity concentration of 50 mu Ci/mL). Conclusions: On the basis of cytology experiments, it was found that I-131-BmK CT could specifically conjugate with C6 glioma cell and inhibit cell growth. Hence, it may be used as a glioma-targeted agent.
引用
收藏
页码:353 / 359
页数:7
相关论文
共 50 条
  • [21] Preparation and use of 131I MAGIC gel as a dosimeter for targeted radionuclide therapy
    Courbon, Frederic
    Love, Peter
    Chittenden, Sarah
    Flux, Glen
    Ravel, Patrice
    Cook, Gary
    CANCER BIOTHERAPY AND RADIOPHARMACEUTICALS, 2006, 21 (05) : 427 - 436
  • [22] [131I] ICF01012, a potential agent for targeted radionuclide therapy of melanoma
    Bonnet, M.
    Papon, J.
    Mishellany, F.
    Labarre, P.
    Maublant, J.
    Miot-Noirault, E.
    Cayre, A.
    Madelmont, J. C.
    Chezal, J. M.
    Moins, N.
    JOURNAL OF NUCLEAR MEDICINE, 2009, 50
  • [23] Preparation and preclinical evaluation of 131I-trastuzumab for breast cancer
    Kameswaran, Mythili
    Gota, Vikram
    Ambade, Rajwardhan
    Gupta, Sudeep
    Dash, Ashutosh
    JOURNAL OF LABELLED COMPOUNDS & RADIOPHARMACEUTICALS, 2017, 60 (01): : 12 - 19
  • [24] Preparation and Evaluation of SDF-1-targeted Ultrasound Contrast Agent
    Mu, Yuming
    Wang, Meng
    Shi, Qi
    Adi, Tuerxunnayi
    JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY, 2015, 66 (16) : C253 - C253
  • [25] Preparation and preliminary evaluation study of [131I]iodocolchicine-gallic-AuNPs: a potential scintigraphic agent for inflammation detection
    Essa, Basma M.
    Selim, Adli A.
    El-Kawy, O. A.
    Abdelaziz, Gamal
    INTERNATIONAL JOURNAL OF RADIATION BIOLOGY, 2022, 98 (08) : 1358 - 1365
  • [26] Preparation and in vitro evaluation of radioiodinated bakuchiol as an anti tumor agent
    Bapat, K
    Chintalwar, GJ
    Pandey, U
    Thakur, VS
    Sarma, HD
    Samuel, G
    Pillai, MRA
    Chattopadhyay, S
    Venkatesh, M
    APPLIED RADIATION AND ISOTOPES, 2005, 62 (03) : 389 - 393
  • [27] Preclinical Evaluation of an 131I-Labeled Benzamide for Targeted Radiotherapy of Metastatic Melanoma
    Joyal, John L.
    Barrett, John A.
    Marquis, John C.
    Chen, Jianqing
    Hillier, Shawn M.
    Maresca, Kevin P.
    Boyd, Marie
    Gage, Kenneth
    Nimmagadda, Sridhar
    Kronauge, James F.
    Friebe, Matthias
    Dinkelborg, Ludger
    Stubbs, James B.
    Stabin, Michael G.
    Mairs, Rob
    Pomper, Martin G.
    Babich, John W.
    CANCER RESEARCH, 2010, 70 (10) : 4045 - 4053
  • [28] PREPARATION AND EVALUATION OF I-131 TETRACYCLINE AS A TUMOR SCANNING AGENT .2. UPTAKE IN VIABLE AND NON-VIABLE TUMOR
    CHAUNCEY, D
    HALPERN, SE
    HAGAN, P
    ALAZRAKI, NP
    JOURNAL OF NUCLEAR MEDICINE, 1975, 16 (06) : 520 - 520
  • [29] In-vitro uptake of radioactive lipiodol I-131 and I-125 by hepatoblastoma: implications for targeted radiotherapy
    Towu, E
    Boxer, G
    Begent, R
    Zweit, J
    Spitz, L
    Hobbs, K
    Winslet, M
    PEDIATRIC SURGERY INTERNATIONAL, 2001, 17 (08) : 609 - 613
  • [30] In-vitro uptake of radioactive lipiodol I-131 and I-125 by hepatoblastoma: implications for targeted radiotherapy
    E. Towu
    G. Boxer
    R. Begent
    J. Zweit
    L. Spitz
    K. Hobbs
    M. Winslet
    Pediatric Surgery International, 2001, 17 : 609 - 613